MUSC treats emphysema patient with lung coils
Charlie Strange, M.D., an MUSC professor, treated the first patient in the United States in the RENEW study, which is evaluating the use of PneumRx Inc.'s RePneu lung volume reduction coil in patients with severe emphysema.
The RePneu LVRC, a minimally invasive medical implant designed to treat the symptoms of severe emphysema, is intended to improve lung function, exercise ability and quality of life for patients.
|The RePneu lung volume reduction coil is implanted in a patient's lung in order to treat the symptoms of severe emphysema. MUSC's Dr. Charlie Strange treated the first United States patient with the coils.|
"After learning the LVRC procedure in Europe, I am thrilled to offer this innovative treatment through our team at MUSC," said Strange, MUSC professor of pulmonary and critical care, allergy and sleep medicine, and principal investigator for the RENEW study.
The coils are offered through a prospective, randomized research trial for patients with lung hyperinflation from emphysema. Ten coils are placed in one lung lobe with severe emphysema to reduce the size of the hyper-inflated lung and to give it more elastic recoil. The other lung is treated after four months.
The LVRC procedure remains investigational and can only be accessed in South Carolina through the MUSC trial. MUSC's South Carolina Clinical and Translational Research Institute negotiated facility access and expedited the research timeline to make the study possible.
Although the LVRC is undergoing clinical evaluation in the United States, it has been used in Europe since 2008. The technology is CE-mark [a mandatory conformity marking for products sold in the European Economic Area since 1993] approved in Europe and routinely available to treat patients in Germany. It was the only emphysema treatment method selected in 2012 by the French Ministry of Health to undergo a multi-center cost-effectiveness study in France. Unlike other minimally invasive devices designed to treat emphysema, the RePneu LVRC is intended to treat a broad range of emphysema patients, including those with heterogeneous and homogeneous disease, in both upper and lower lobes. It also performs independently of collateral ventilation, a common condition in emphysema patients.
For information about MUSC's SCTR Institute, email email@example.com or call 792-8300. To learn more about the LVRC and the study, visit www.pneumrx.com or http://tinyurl.com/d35ep5m.